Ratings by Evercore ISI (Gavin Clark-Gartner)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/27/2026 | Forte Biosciences Inc. | FBRX | Downgrade | In Line (Outperform) |
54.78 (76.53) |
39.7% | Details | |
| 7/22/2026 | Tenax Therapeutics | TENX | New Coverage | Outperform (N/A) |
15.72 (14.82) |
-5.73% | Details | |
| 7/8/2026 | Crinetics | CRNX | Downgrade | In Line (Outperform) |
42.03 (83.88) |
99.57% | Details | |
| 6/22/2026 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/26/2026 | Avalyn Pharma | AVLN | New Coverage | Outperform (N/A) |
28.84 (28.10) |
-2.57% | Details | |
| 5/15/2026 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2026 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2026 | Sarepta Therapeutics | SRPT | Maintain | In Line (N/A) |
|
Details | ||
| 5/15/2026 | Dyne Therapeutics | DYN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2026 | Crinetics | CRNX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2026 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2026 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2026 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2026 | Mirum Pharmaceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Sarepta Therapeutics | SRPT | Maintain | In Line (N/A) |
|
Details | ||
| 4/13/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/2/2026 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Damora Therapeutics | DMRA | New Coverage | Outperform (N/A) |
23.92 (28.33) |
18.44% | Details | |
| 3/4/2026 | Mirum Pharmaceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2026 | Mirum Pharmaceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2026 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2026 | BioCryst Pharma | BCRX | New Coverage | Outperform (N/A) |
6.95 (9.53) |
37.12% | Details | |
| 2/18/2026 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2026 | Evommune Inc | EVMN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2026 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/5/2026 | Crinetics | CRNX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/18/2025 | Avidity Biosciences | RNA | Downgrade | In Line (Outperform) |
71.97 (11.18) |
-84.47% | Details | |
| 12/1/2025 | Evommune Inc | EVMN | New Coverage | Outperform (N/A) |
20.71 (11.05) |
-46.64% | Details | |
| 11/25/2025 | Forte Biosciences Inc. | FBRX | New Coverage | Outperform (N/A) |
19.06 (54.78) |
187.41% | Details | |
| 10/1/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 10/1/2025 | Astria Therapeutics | ATXS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/1/2025 | Travere Therapeutics | TVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/1/2025 | BioCryst Pharma | BCRX | Downgrade | In Line (Outperform) |
7.59 (9.53) |
25.56% | Details | |
| 8/25/2025 | Insmed | INSM | New Coverage | Outperform (N/A) |
131.88 (103.12) |
-21.81% | Details | |
| 8/25/2025 | Travere Therapeutics | TVTX | New Coverage | Outperform (N/A) |
17.92 (55.56) |
210.04% | Details | |
| 8/25/2025 | Astria Therapeutics | ATXS | New Coverage | Outperform (N/A) |
6.79 (12.58) |
85.27% | Details | |
| 8/25/2025 | Vera Therapeutics | VERA | New Coverage | Outperform (N/A) |
22.57 (32.51) |
44.04% | Details | |
| 8/25/2025 | Ultragenyx Pharma | RARE | New Coverage | Outperform (N/A) |
29.78 (25.00) |
-16.05% | Details | |
| 8/25/2025 | BioCryst Pharma | BCRX | New Coverage | Outperform (N/A) |
8.56 (7.59) |
-11.33% | Details | |
| 7/7/2025 | Jasper Therapeutics | JSPR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/17/2025 | Sarepta Therapeutics | SRPT | Maintain | In Line (N/A) |
|
Details | ||
| 5/29/2025 | Dyne Therapeutics | DYN | New Coverage | Outperform (N/A) |
11.76 (25.10) |
113.44% | Details | |
| 5/8/2025 | Sarepta Therapeutics | SRPT | Downgrade | In Line (Outperform) |
36.72 (15.54) |
-57.68% | Details | |
| 5/8/2025 | Mirum Pharamceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 4/29/2025 | ProQR Therapeutics N.V. | PRQR | New Coverage | Outperform (N/A) |
1.43 (1.73) |
20.98% | Details | |
| 1/28/2025 | MindMed | MNMD | New Coverage | Outperform (N/A) |
6.90 (15.02) |
117.68% | Details | |
| 11/20/2024 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2024 | Foghorn Therapeutics | FHTX | New Coverage | Outperform (N/A) |
6.20 (4.74) |
-23.55% | Details | |
| 8/8/2024 | Sarepta Therapeutics | SRPT | Upgrade | Outperform (In Line) |
140.06 (36.72) |
-73.78% | Details | |
| 6/17/2024 | Mirum Pharamceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 4/3/2024 | Jasper Therapeutics | JSPR | New Coverage | Outperform (N/A) |
26.20 (0.60) |
-97.71% | Details | |
| 2/26/2024 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/2/2024 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Outperform (N/A) |
|
Details | ||
| 12/22/2023 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Outperform (N/A) |
|
Details | ||
| 12/21/2023 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2023 | Mirum Pharamceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2023 | Aclaris Therapeutis | ACRS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2023 | Sarepta Therapeutics | SRPT | Maintain | In Line (N/A) |
|
Details | ||
| 10/17/2023 | Mirum Pharamceuticals | MIRM | New Coverage | Outperform (N/A) |
27.89 (107.57) |
285.69% | Details | |
| 10/3/2023 | Aclaris Therapeutis | ACRS | New Coverage | Outperform (N/A) |
6.49 (5.12) |
-21.11% | Details | |
| 7/17/2023 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/17/2023 | argenx SE | ARGX | New Coverage | Outperform (N/A) |
379.08 (882.56) |
132.82% | Details | |
| 6/23/2023 | Sarepta Therapeutics | SRPT | Downgrade | In Line (Outperform) |
123.92 (140.06) |
13.02% | Details | |
| 5/30/2023 | C4 Therapeutics | CCCC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/30/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/9/2023 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/23/2023 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2022 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details |
